Hospital readmissions among adults with chronic kidney disease by HIV status in the United States

美国慢性肾病成人患者按 HIV 感染状况划分的医院再入院率

阅读:3

Abstract

OBJECTIVE: To characterize all-cause unplanned 30-day readmissions among adults with chronic kidney disease (CKD) of all-stages by HIV status in the United States. DESIGN: A retrospective cohort study using the Nationwide Readmissions Database-an all-payer nationally representative database. METHODS: Index (i.e., initial) admissions and readmissions were defined following the United States Centers for Medicare & Medicaid Services (CMS) guidelines. We evaluated trends in the readmission risk among adults by CKD and HIV status during 2016-2022 and compared the overall and subgroup-specific readmission risk by HIV status among adults with CKD in 2022. Crude and age and sex-adjusted risk ratios (aRRs) were calculated using average marginal estimates from mixed-effect logistic regressions. Survey weights were applied. RESULTS: Among people with CKD, the readmission risk declined from 33.4% in 2016 to 29.1% in 2022 for people with HIV (PWH) and declined from 23.7% in 2016 to 21.9% in 2022 for people without HIV (PWoH). In 2022, there were 43 087 index admissions from PWH and 5 170 351 from PWoH. PWH were more likely to be men, younger, have end-stage CKD, and reside in low-income areas vs. PWoH. For both PWH and PWoH, the readmission risk increased with more advanced CKD stages but decreased with older age. In 2022, PWH were more likely to be readmitted than PWoH (aRR = 1.20 [95% confidence interval, 95% CI: 1.17-1.23]). This disparity was greater among those less than 40 years of age (aRR = 1.32 [95% CI: 1.23-1.42]). CONCLUSION: More efforts are needed to mitigate the excessive readmission burden of people with CKD. PWH, especially young individuals, could represent a critical group for intensified intervention in CKD readmission prevention programs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。